The inhibition of the mTOR signaling pathway in tumors by zotarolimus reduced CD44, EGFR, TGF-β, and VEGF expression, which could decelerate the migration and invasion of tumor cells in cancer metastasis. This evidence concerns the gene CD44 and cancer.